An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice

被引:19
作者
Brühl, P
Kerschbaum, A
Eibl, MM
Mannhalter, JW
机构
[1] Immuno AG Wien, Dept Immunol Res, A-1221 Vienna, Austria
[2] Univ Vienna, Inst Immunol, Vienna, Austria
关键词
D O I
10.1089/aid.1998.14.401
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Induction of mucosal as well as systemic immunity to HIV-1 is considered to have high priority in current concepts of future AIDS vaccines, Here we show that the desired immune responses can be elicited by an experimental prime-boost regimen consisting of mucosal (intragastric) application of a recombinant vaccinia virus carrying the HIV-1 env gene (vSC25), followed by parenteral (intradermal) immunization with the recombinant HIV-1 glycoprotein 160 (rgp160), Following intragastric immunization of mice with vSC25 in combination with the mucosal adjuvant cholera toxin (CT), HIV-1 env-specific IgA was secreted by B cells of Peyer's patches and the lamina propria, Moreover, mucosal (intragastric and intranasal) application of vSC25 (both in presence or absence of CT) induced a long-lasting, HIV-1 env-specific systemic cytotoxic T cell response. Subsequent intradermal boosters with rgp160 led to HIV-1-specific T cell memory and serum antibodies.
引用
收藏
页码:401 / 407
页数:7
相关论文
共 47 条
[1]   HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy [J].
Ada, GL ;
McElrath, MJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (03) :205-210
[2]   LARGE-SCALE PRODUCTION AND PURIFICATION OF A VACCINIA RECOMBINANT-DERIVED HIV-1 GP160 AND ANALYSIS OF ITS IMMUNOGENICITY [J].
BARRETT, N ;
MITTERER, A ;
MUNDT, W ;
EIBL, J ;
EIBL, M ;
GALLO, RC ;
MOSS, B ;
DORNER, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1989, 5 (02) :159-171
[3]  
BEAGLEY KW, 1988, J IMMUNOL, V141, P2035
[4]   NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZED WITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1 [J].
BELSHE, RB ;
GRAHAM, BS ;
KEEFER, MC ;
GORSE, GJ ;
WRIGHT, P ;
DOLIN, R ;
MATTHEWS, T ;
WEINHOLD, K ;
BOLOGNESI, DP ;
SPOSTO, R ;
STABLEIN, DM ;
TWADDELL, T ;
BERMAN, PW ;
GREGORY, T ;
IZU, AE ;
WALKER, MC ;
FAST, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :475-480
[5]   SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION [J].
BELSHE, RB ;
CLEMENTS, ML ;
DOLIN, R ;
GRAHAM, BS ;
MCELRATH, J ;
GORSE, GJ ;
SCHWARTZ, D ;
KEEFER, MC ;
WRIGHT, P ;
COREY, L ;
BOLOGNESI, DP ;
MATTHEWS, TJ ;
STABLEIN, DM ;
OBRIEN, FS ;
EIBL, M ;
DORNER, F ;
KOFF, W .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1387-1395
[6]   Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza [J].
Bender, BS ;
Rowe, CA ;
Taylor, SF ;
Wyatt, LS ;
Moss, B ;
Small, PA .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6418-6424
[7]  
BOWEN JC, 1994, IMMUNOLOGY, V81, P338
[8]   EXPRESSION OF THE HTLV-III ENVELOPE GENE BY A RECOMBINANT VACCINIA VIRUS [J].
CHAKRABARTI, S ;
ROBERTGUROFF, M ;
WONGSTAAL, F ;
GALLO, RC ;
MOSS, B .
NATURE, 1986, 320 (6062) :535-537
[9]   AIDS vaccine - Looking for leads in HIV's battle with immune system [J].
Cohen, J .
SCIENCE, 1997, 276 (5316) :1196-1197
[10]   ENHANCED IMMUNITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE ELICITED BY A COMBINED VACCINE REGIMEN CONSISTING OF PRIMING WITH A VACCINIA RECOMBINANT EXPRESSING HIV ENVELOPE AND BOOSTING WITH GP160-PROTEIN [J].
COONEY, EL ;
MCELRATH, MJ ;
COREY, L ;
HU, SL ;
COLLIER, AC ;
ARDITTI, D ;
HOFFMAN, M ;
COOMBS, RW ;
SMITH, GE ;
GREENBERG, PD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1882-1886